Narrative
发表于 2025-3-23 12:42:06
Book 2015the field. It opens by providing an overview of the recommendations in the most recent consensus paper from the European Germ Cell Cancer Consensus Group, which is based on interdisciplinary cooperation among urologists, medical oncologists, radio-oncologists, pathologists, and basic scientists. The
CURB
发表于 2025-3-23 14:07:28
Latest Recommendations of the European Germ Cell Cancer Group on Diagnosis and Treatment of Germ Cele et al. Eur Urol 53:497–513, 2008), the latest published in 2012 (Beyer et al. Ann Oncol 24:878–888, 2013). In this chapter, the recent recommendations of the European group are summarized. The following chapters will present some topics in detail, which are still discussed controversial, or for which the best management is not yet found.
Innocence
发表于 2025-3-23 20:03:26
How Should Patients with Recurrent Disease Be Treated Actually?of HDCT as first-line salvage therapy in relapsed patients with highly favorable risk profiles. In order to avoid overtreatment, HDCT should only be administered at specialist centres with the necessary expertise.
PLIC
发表于 2025-3-23 23:23:39
Prognostic Factors at Initial Presentation and in Recurrent Diseaseisease. This discussion has been presented in the previous chapters of this book. The other one will be presented here and focuses on the much more pressing question of survival probabilities in patients with metastatic disease.
Anemia
发表于 2025-3-24 06:26:25
https://doi.org/10.1007/978-1-4842-9830-5 follow-up has to be tailored to each individual patient, and the schedule has to be acceptable for the patient, the physician, as well as the health-care system . The interval of follow-up visits and the tests to be performed at each visit depend on the risk of relapse in general and on the likely site of relapse in particular .
ALLEY
发表于 2025-3-24 09:42:41
http://reply.papertrans.cn/28/2706/270582/270582_16.png
Robust
发表于 2025-3-24 13:05:45
http://reply.papertrans.cn/28/2706/270582/270582_17.png
consolidate
发表于 2025-3-24 14:54:26
http://reply.papertrans.cn/28/2706/270582/270582_18.png
NEX
发表于 2025-3-24 22:42:48
http://reply.papertrans.cn/28/2706/270582/270582_19.png
NOT
发表于 2025-3-25 01:06:34
https://doi.org/10.1007/978-1-4842-9830-5isease. This discussion has been presented in the previous chapters of this book. The other one will be presented here and focuses on the much more pressing question of survival probabilities in patients with metastatic disease.